Relapsed AML 2009

Author: Prof. Dr. med. Dirk Reinhardt, 05.08.2009, erstellt am: 2009/12/01, Last modification: 2015/06/11

Title International Registry Relapsed AML 2009, Registry of children and adolescents with relapsed or refractory acute myeloid leukeamia (AML), AML-BFM Study Group
Disease Relapsed or refractory acute myeloid leukeamia (AML)
Type International Registry for children and adolescents with relapsed or refractory AML
Problem / Objectives
Therapy / Study arms
Inclusion Criteria
Exclusion Criteria
Recruitment ca. 100 patients / year
Status Start 18.06.2009. The registy will be closed, as soon as a phase-III- trial for theese group of patients will be opened.
EudraCT 2010-018980-41
Entry Study Register
Principal Investigator Prof. Dirk Reinhardt
E-Mail mailto:aml-bfm@uke-essen.de
URL http://aml.mh-hannover.de/
Contact

Coordination

Prof. Dr. med. Dirk Reinhardt
Universitätsklinikum Essen (AöR)
Klinik für Kinderheilkunde III
Hufelandstraße 55
45147 Essen
Telefon +49 (201) 723 3784
Fax +49 (201) 723 5386
dirk.reinhardt@uk-essen.de

Prof. Dr. med. U Creutzig

Documentation

Katharina Röllecke
Universitätsklinikum Essen (AöR)
Klinik für Kinderheilkunde III
Hufelandstraße 55
45147 Essen
Telefon +49 (0) 201 74 94 96 13
Fax +49 (0) 201 8 777 54 84
Roellecke.Katharina@aml-bfm.de

Statistics

Dr. rer. hort. Martin Zimmermann
Medizinische Hochschule Hannover
Kinderklinik IV, Päd. Onkologie
Carl-Neuberg-Straße 1
30625 Hannover
Telefon +49 (511) 532 3764
Fax +49 (511) 532 90 29
zimmermann.martin@mh-hannover.de

Participants AIEOP, Italy BFM-A, Austria BFM-G, Germany BSPHO (Belgium) CPH, Czech Republic Croatia DCOG, the Netherlands Greece Hungary Ireland LAME (France) NOPHO, Nordic countries PPLLSG, Poland Serbia Slovakia Slovenia SHOP, Spain SPOG, Switzerland NCRI, United Kingdom
Weitere Informationen San­der A, Zim­mer­mann M, Dworz­ak M, Fleisch­hack G, von Neu­hoff C, Rein­hardt D, Kas­pers GJ, Creut­zig U: Con­se­quent and in­ten­si­fied re­l­ap­se the­ra­py im­pro­ved sur­vi­val in pe­d­ia­tric AML: re­sults of re­l­ap­se tre­at­ment in 379 pa­ti­ents of th­ree conse­cu­ti­ve AML-BFM tri­als. Leu­ke­mia 2010
Link(s) Literature on AML
Sponsoring Sponsor: GPOH GgmbH